COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
Proxy Voting and the Rise of ESGAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact CERF/CF Admin. We track the temporal pattern of institutional investors’ ideologies as revealed by their proxy votes from 2005 to 2018. Despite the financial crisis, the regulatory changes on proxy voting and transformation of the asset management industry it has spawned, and despite the rise of the socially responsible investment movement, we find that the ideology of the largest investors has remained highly stable. The ideologies of institutional investors are revealed by a dynamic, spatial scaling analysis of all proxy votes of 561mutual fund families. We characterize voting as driven by single-peaked preferences in a two-dimensional Euclidean space. One dimension reflects the familiar left-right ideological leanings, with more socially responsible investors on the left, and the other dimension differences in attitudes towards management, with management-friendly investors at one end and management-disciplinarians at the other. Although the ideology of the largest investors remains solidly stable on average, we find that the ideologies of a substantial fraction of other investors evolve substantially over time. This talk is part of the CERF and CF Events series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsActive Materials organoids Henry Martyn LecturesOther talksThe Anne McLaren Lecture: Embryonic and adult neural stem cells- what underlies their difference The algorithmic strength of planar graph colouring theorems The Liverpool Mass Asymptomatic Testing Pilot Study and Measuring Sensitivity in the Real World Adapting the Fokas transform method to solve certain fractional PDEs Empire of inequality: the politics of taxation in the French colonial empire, 1900-1950s Hh signalling and the anti-tumour immune response: biology and new treatment opportunities |